Effect of cyclosporine in a murine model of experimental colitis

Digestive Diseases and Sciences

Volumn 47, Issue 6, 2002, Pages 1362-1368

  Banić, Marko ^a   Anić, Branimir ^b   Brkić, Tomislav ^b   Ljubicić, Neven ^c   Plesko, Sanja ^d   Dohoczky, Csaba ^e   Erceg, Damir ^e   Petrovecki, Mladen ^f   Stipancić, Igor ^a   Rotkvić, Ivo ^b  

^a University of Zagreb School of Medicine   (Croatia)

^b KBC Zagreb   (Croatia)

^c SESTRE MILOSRDNICE UNIVERSITY HOSPITAL   (Croatia)

^d Croatia   (Croatia)

^e PLIV A Research Institute   (Croatia)

^f UNIVERSITY OF RIJEKA   (Croatia)

Author keywords

Cyclosporine A; Experimentalcolitis; Inflammation; Inflammatory bowel disease

Indexed keywords

1 FLUORO 2,4 DINITROBENZENE; CYCLOSPORIN A; ENEMA; IMMUNOSUPPRESSIVE AGENT;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLITIS; COLON MUCOSA; CONTROLLED STUDY; DRUG EFFECT; ENTERITIS; EXPERIMENTAL MODEL; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; INTRACOLONIC DRUG ADMINISTRATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; COLITIS; COLON; CYCLOSPORINE; DISEASE MODELS, ANIMAL; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE AGENTS; INTESTINAL MUCOSA; MALE; MICE; MICE, INBRED STRAINS;

EID: 0036277141     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1015339018181     Document Type: Article

References (30)

1. Infliximab for treatment of fistulas in patients with Crohn's disease
2. Thalidomide therapy for patients with refractory Crohn's disease: An open label trial
3. An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease
4. Cyclosporine for inflammatory bowel disease: Mechanisms and possible actions
5. Inflammatory bowel diseases: A breakdown of central and peripheral immunological homeostasis
6. A model of inflammatory bowel disease induced by 2,4-dinitrofluorobenzene in previously sensitized BALB/c mice
7. Effect of methylprednisolone on small bowel, spleen and liver changes in murine model of inflammatory bowel disease
8. Canadian consensus meeting on cyclosporine monitoring: Report of the consensus panel
9. Intestinal lymphocyte subpopulations in inflammatory bowel disease by immunohistochemical and cell isolation techniques
10. Dietary fish oil reduces progression of chronic inflammatory lesions in a rat model of granulomatous colitis
11. BPC-15 reduces trinitrobenzene sulfonic acid-induced colonic damage in rats
12. Immunohistochemical characterization, distribution and ultrastructure of lymphocyte bearing T-cell receptor gamma/delta in inflammatory bowel disease
13. Experimental colitis in animal models
14. Experimental models of inflammatory bowel disease
15. Experimental models of intestinal inflammation. New insights into mechanisms of mucosal homeostasis
16. Inhibition of leukotriene synthesis markedly accelerates healing in a rat model of inflammatory bowel disease
17. Hapten-induced model of chronic inflammation and ulceration in rat colon
18. Skin granuloma in mice immunosupressed by cyclosporine
19. Insensitivity towards inhibition by cyclosporine A, rapamycin and tacrolimus in human intestinal lamina propria T-lymphocytes
20. Cyclosporine in severe ulcerative colitis refractory to steroid therapy
21. Low-dose cyclosporine for the treatment of Crohn's disease
22. A critical review of cyclosporine therapy in inflammatory bowel disease
23. Cyclosporine-induced autoimmunity. Conditions for expressing disease, requirement for intact thymus and potency estimates of autoimmune lymphocytes in drug treated rats
24. Cyclosporine A-induced autoimmune disease in mice
25. Selective modulation of T-cell responses in autoimmunitiy and cancer
26. The pharmacokinetics and colon tissue concentrations of cyclosporine after IV, oral and enema administration
27. Interleukin-2 activity of colonic lamina propria mononuclear cells in a rat model of experimental colitis